GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedPacto Inc (XKRX:235980) » Definitions » EV-to-EBIT

MedPacto (XKRX:235980) EV-to-EBIT : -4.75 (As of Jun. 02, 2025)


View and export this data going back to 2019. Start your Free Trial

What is MedPacto EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MedPacto's Enterprise Value is ₩67,101.7 Mil. MedPacto's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-14,136.3 Mil. Therefore, MedPacto's EV-to-EBIT for today is -4.75.

The historical rank and industry rank for MedPacto's EV-to-EBIT or its related term are showing as below:

XKRX:235980' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.99   Med: -3.87   Max: -3.64
Current: -4.75

During the past 7 years, the highest EV-to-EBIT of MedPacto was -3.64. The lowest was -4.99. And the median was -3.87.

XKRX:235980's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs XKRX:235980: -4.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MedPacto's Enterprise Value for the quarter that ended in Mar. 2025 was ₩51,151.8 Mil. MedPacto's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-14,136.3 Mil. MedPacto's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -27.64%.


MedPacto EV-to-EBIT Historical Data

The historical data trend for MedPacto's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedPacto EV-to-EBIT Chart

MedPacto Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -28.28 -92.79 -122.06 -16.66 -4.97

MedPacto Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.36 -6.44 -6.33 -4.76 -3.62

Competitive Comparison of MedPacto's EV-to-EBIT

For the Biotechnology subindustry, MedPacto's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedPacto's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedPacto's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MedPacto's EV-to-EBIT falls into.


;
;

MedPacto EV-to-EBIT Calculation

MedPacto's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=67101.705/-14136.252
=-4.75

MedPacto's current Enterprise Value is ₩67,101.7 Mil.
MedPacto's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-14,136.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedPacto  (XKRX:235980) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MedPacto's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-14136.252/51151.808
=-27.64 %

MedPacto's Enterprise Value for the quarter that ended in Mar. 2025 was ₩51,151.8 Mil.
MedPacto's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-14,136.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedPacto EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MedPacto's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MedPacto Business Description

Traded in Other Exchanges
N/A
Address
92 Myeongdal -ro, Seocho-gu, Borim Building, Seoul, KOR
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.

MedPacto Headlines

No Headlines